Overview of Нимика

Property	Description
Active ingredient	Nimesulide
Form	Tablet, granule for oral suspension, gel, suppository
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Relief of pain, inflammation, and fever
Origin	Synthetic compound

What Type of Medicine is Нимика (Nimesulide)?

Нимика is a pharmaceutical preparation whose active substance is Nimesulide, placing it in the Nonsteroidal Anti-inflammatory Drug (NSAID) pharmacological class. Nimesulide is classified as a non-opioid analgesic and antipyretic agent. This classification defines its core function as a medication designed to modulate the body's response to inflammation and pain.

The active substance, Nimesulide, is a synthetic compound chemically derived from the sulfonanilide class of chemicals. Its defining characteristic is its primary role as a selective cyclooxygenase-2 (COX-2) inhibitor, a mechanism that targets the enzyme chiefly responsible for initiating inflammatory and pain signals in the body. The drug entity is made available in forms allowing for both systemic (such as oral forms) and topical routes of administration.

What is the General Purpose of Нимика?

The general purpose of the Nimesulide compound is to provide a triple therapeutic effect: to achieve analgesia (pain relief), deliver an anti-inflammatory effect (reducing local swelling and redness), and act as an antipyretic (reducing fever). Nimesulide is included in the Anatomical Therapeutic Chemical (ATC) classification under the heading for anti-inflammatory and antirheumatic products. This drug’s primary role is recognized for managing symptoms of inflammation and associated discomfort.

This combination of effects establishes Нимика as an agent focused on the management of the acute symptomatic triad of pain, inflammation, and elevated body temperature. As a single active ingredient product, Nimesulide is combined with specific pharmaceutical excipients—the base/vehicle—required to produce stable and deliverable forms like the tablet, granule for oral suspension, and gel.

What side effects are possible with Нимика?

Possible Side Effects and Safety Information: Nimesulide

This section outlines the officially documented adverse effects and safety restrictions for Nimesulide (assumed Нимика), based strictly on governmental regulatory documents (e.g., EMA-derived Summary of Product Characteristics). It does not contain dosing or therapeutic advice.

Serious Safety Risks and Restrictions

The most significant risks documented by regulatory bodies involve serious damage to the liver (hepatotoxicity) and complications in the gastrointestinal tract, such as bleeding, ulceration, or perforation, which can be fatal.

Due to these risks, regulatory approval often limits its use to second-line treatment for acute pain and primary dysmenorrhea. Treatment is strictly limited to the lowest effective dose for a maximum duration of 15 days.

Common and Less Common Side Effects

Adverse reactions are classified by frequency in official labels:

Frequency	System Organ Class	Common Reactions (1/100 to 1/10)
Common	Gastrointestinal	Diarrhea, Nausea, Vomiting
Common	Hepato-biliary	Increased liver enzymes (usually transient)
Uncommon	Gastrointestinal	Constipation, Flatulence, Ulcers, Bleeding
Uncommon	Skin	Rash, Pruritus, Increased sweating, Edema

Very rare reactions include serious events like fulminant hepatitis, severe skin reactions (e.g., Stevens-Johnson syndrome), and severe renal failure. Patients are instructed to immediately discontinue the medicine and seek attention if symptoms of liver injury (e.g., dark urine, fatigue, jaundice) or bleeding occur.

Population and Restriction Notes

Nimesulide is contraindicated in patients with active liver disease, history of hepatotoxic reactions, severe heart or kidney failure, active ulcers, and during the third trimester of pregnancy. Caution is advised for the elderly due to increased risk of gastrointestinal complications.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Nimesulide is documented to involve specific clinical manifestations and carries the risk of severe systemic outcomes. Documented signs of acute overdose include gastrointestinal effects such as nausea, vomiting, and upper abdominal pain, along with the potential for gastrointestinal bleeding, ulceration, or perforation. Central nervous system effects may present as drowsiness, lethargy, dizziness, confusion, and disorientation. Intoxication from the topical formulation is not expected due to low systemic exposure.

The most serious outcomes reported in regulatory documents include acute liver failure and other serious hepatic reactions, which have resulted in very rare fatal cases. Deterioration of renal function is also a documented complication, particularly in susceptible populations such as the elderly.

Regulatory authorities mandate that any patient suspected of overdose must seek immediate medical attention without delay, as urgent hospital treatment is likely to be needed. Since no specific antidote is known, management focuses entirely on symptomatic and supportive treatment. This may involve procedures such as gastric lavage or administering activated charcoal to reduce absorption, and it requires mandatory monitoring of renal and hepatic function throughout the treatment period.

Therapeutic Uses of Нимика

What Нимика Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for symptom clusters related to pain, inflammation, and fever. It is commonly utilized where short-term symptomatic assistance is required. The medication is considered relevant for easing acute pain, supporting symptomatic management in painful episodes of osteoarthritis, and addressing discomfort linked to primary dysmenorrhoea (menstrual pain).

“The application of this medication is aligned with supporting patients who experience acute, disruptive symptom manifestations.”

Symptomatic Support and Comfort

This medication is applied in addressing symptom clusters that may become disruptive, including those related to soft tissue injuries, post-operative discomfort, and low back pain. It is relevant when supportive symptom management is appropriate, offering symptomatic relief that may assist patients with symptom fluctuations and may help maintain a sense of stability during periods of heightened discomfort.

Quick Fact: Relief for Pain, Inflammation, and Fever
This medication plays a role in managing symptoms related to inflammatory or irritative states, which supports general well-being during symptomatic phases.

Regulatory References

European Medicines Agency overview on Nimesulide uses

Eligibility and Restrictions for Use

Who can and cannot use Nicardipine (Нимика) — Official Eligibility

Nicardipine (marketed as Нимика in some regions) is a medicine used to treat high blood pressure, and official regulatory documents define strict criteria for its use.

Populations Who MUST NOT Use Nicardipine (Contraindicated):

Use of this medicine is strictly contraindicated (prohibited) for patients with:

Advanced Aortic Stenosis (a severe narrowing of the aortic valve).
Known hypersensitivity or allergy to nicardipine or any ingredients in the formulation.
Unstable Angina or those immediately following a myocardial infarction (heart attack).

Populations Requiring Special Caution/Consideration:

Use of nicardipine requires caution and close monitoring in certain groups, including:

Patients with Impaired Hepatic (Liver) or Renal (Kidney) Function: Lower starting doses are often necessary.
Patients with Congestive Heart Failure or significant left ventricular dysfunction.
The Elderly (Geriatric Patients): Increased caution is advised due to the risk of severe hypotension.

Age and State Restrictions:

Pediatric Patients (Under 18 Years): The safety and effectiveness in this age group have not been established.
Pregnancy and Lactation: Use during pregnancy is generally limited to cases where the benefit outweighs the potential risk to the fetus. It is generally not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Drug interactions with nimodipine (Nimika) are primarily governed by its metabolism through the Cytochrome P450 CYP3A4 enzyme system. These interactions necessitate careful consideration of co-administered substances, as documented in regulatory labeling.

Contraindicated and High-Risk Combinations

Co-administration with strong CYP3A4 inducers is contraindicated due to the severe risk of therapeutic failure resulting from significantly reduced nimodipine plasma concentrations. Contraindicated substances include the antibiotic rifampicin and specific anti-epileptic drugs such as phenobarbital, phenytoin, and carbamazepine.

Significant Pharmacokinetic Interactions

Interaction Type	Interacting Substance Examples	Implication
Increased Exposure (Inhibition)	Azole antimycotics (e.g., ketoconazole), Macrolide antibiotics (e.g., erythromycin), HIV protease inhibitors	Requires close monitoring due to substantially elevated nimodipine concentrations.
Decreased Exposure (Induction)	St. John's Wort	Must be avoided due to risk of reduced efficacy.

Pharmacodynamic and Product Interactions

Nimodipine may potentiate the effects of concomitantly administered blood pressure-lowering agents, leading to additive hypotensive effects. Co-administration with potentially nephrotoxic drugs may heighten the risk of deteriorated renal function.

Furthermore, grapefruit juice must be avoided as it inhibits CYP3A4, causing a substantial increase in nimodipine plasma levels. Patients with hepatic impairment may also experience naturally increased bioavailability, leading to a higher risk of effects from co-administered agents.

Mechanism of Action

Selective Inhibition of Inflammatory Enzymes

The active mechanism of Nimesulide centers on its ability to act as a selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This enzyme is rapidly produced at sites of molecular stress and is responsible for synthesizing key pro-inflammatory mediators, primarily prostaglandins ( PGE2). This preferential blockade modulates molecular steps by reducing mediator synthesis, which alters subsequent neural signal transmission and local tissue response dynamics.

Modulation of Central and Peripheral Signaling

The drug's mechanism leads to a reduction in PGE2 levels in two key locations: locally, at the peripheral site of tissue irritation, and centrally, within the hypothalamus in the brain. The reduction of PGE2 peripherally influences the threshold of nociceptor activation, and centrally, it modulates the hypothalamic thermoregulatory set-point. This mechanism exerts both peripheral and central pathway modulation, influencing the thermal set-point and nociceptive signal propagation.

Beyond Enzyme Blockade: Inflammatory Gene Regulation

Nimesulide also engages mechanisms that modulate upstream molecular processes, such as the activity of the Nuclear Factor-kappa B ( NF-kappa B) pathway. This influence on NF-kappa B acts on the genetic level to limit the overall transcription and subsequent production of numerous pro-inflammatory proteins. This influence on gene regulation contributes to the attenuation of the full inflammatory molecular response, affecting processes driven by non-prostanoid signaling.

Dosage and Administration Information

How to Use Нимика (Nimesulide)

Systemic use of Nimesulide is characterized by a constrained, short-term course of administration. The medicine is available for systemic use via the oral and rectal routes (tablet, granule, or suppository), as well as a topical gel for local application.

Administration Protocol

Property	Instruction
Route of Administration	Oral or Rectal (Systemic Use).
Standard Systemic Dose	100 mg Nimesulide per dose.
Frequency and Timing	Twice daily (bid). Oral forms are taken after a meal.
Maximum Daily Limit	The total daily dose does not exceed 200 mg.

Constraints and Duration

The overall course of systemic treatment is time-bound, following the principle of using the minimum effective dose for the shortest possible duration. The maximum duration of any single systemic treatment course is 15 days. For formulations like oral granules, the protocol involves dissolution in a liquid before intake.

Population-Specific Use

There is no dosage adjustment for older adults or for adolescents from 12 to 18 years of age. Similarly, patients with mild to moderate renal impairment do not require a change in dose. If a dose is missed, a double dose is not taken to compensate. The use of systemic Nimesulide formulations is prohibited in children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Нимика (Nimesulide)

Evidence for Use in Acute Pain

The research base for Nimesulide includes studies examining acute pain, which primarily consist of short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were applied in research exploring how symptoms change over time, focusing on conditions characterized by acute or disruptive episodes such as sudden muscle discomfort or post-procedure pain. The research primarily examined Adults and Adolescents (usually 12 years and older).

In these research contexts, studies monitored outcomes related to physical discomfort, such as pain intensity measurements. Research describes patterns observed in studies that monitored symptom variability compared to both placebo and other active comparator NSAIDs.

Evidence for Use in Primary Dysmenorrhoea

For symptoms associated with primary dysmenorrhoea (menstrual pain), the evidence base is largely formed by short-term RCTs. These trials were applied in studies examining patient-reported experiences related to conditions characterized by fluctuating manifestations in Adult women and Adolescent girls. Studies monitored outcomes related to episodic or acute changes and utilized patient-reported outcomes describing perceived discomfort to assess changes during the study period.

Evidence for Symptomatic Use in Painful Osteoarthritis Episodes

Research has utilized RCTs to explore outcomes in conditions characterized by symptomatic pain in osteoarthritis (OA). Studies monitored metrics reflecting daily functioning or activity level, alongside measures of pain intensity while moving and at rest. The actual allowed duration of use for this medicine is highly restricted, meaning the results apply only to short-term episodes of heightened symptom activity.

Limitations and Research Gaps

Long-term effects are not fully established for any indication, as the majority of the research evidence is characterized by short-term observation periods (typically no more than two weeks). This focus reflects the necessity to study the compound only for the shortest possible duration. Research provides context on group patterns, but findings describe group patterns, not personal outcomes.

Key Studies & References WHO Collaborating Centre for Drug Statistics Methodology: Nimesulide ATC Classification (M01AX17)

Frequently Asked Questions (FAQ)

Common questions about Нимика (FAQ)

Q: Is Нимика the same as other pain relievers I can buy?

A: Нимика (Nimesulide) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its action differs from non-selective NSAIDs and simple analgesics because regulatory documents describe it as primarily acting as a selective COX-2 inhibitor. This means it preferentially modulates the specific enzyme (COX-2) responsible for inflammation and pain signaling.

Q: Why do doctors prescribe Нимика instead of an alternative?

A: Official regulatory guidance places the use of this medicine in a second-line treatment category for acute pain and menstrual discomfort. This indicates that it is typically considered only when other suitable medicines have either failed or are not deemed appropriate. This limited designation reflects safety considerations documented in official reviews.

Q: Can you take Нимика if you have a known allergy to other similar drugs?

A: Official product information states that Nimesulide is contraindicated if a patient has a history of hypersensitivity reactions to acetylsalicylic acid (Aspirin) or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs). Such reactions include severe symptoms like bronchospasm or rhinitis. Regulatory documents describe a required communication of previous allergic reactions to similar medications to the prescriber.

Q: Can people with high blood pressure use Нимика?

A: Caution is advised for patients with high blood pressure. Official information indicates that, like other NSAIDs, Nimesulide may reduce the effectiveness of certain blood pressure-lowering medications. It is also described as potentially interfering with the effects of diuretics (water tablets).

Q: Why is the drug Нимика restricted or not available in some countries?

A: The medicine’s usage is highly restricted, and it has been withdrawn in some regions, due to regulatory concerns over the risk of serious liver toxicity (hepatotoxicity) and complications in the gastrointestinal tract. Official safety reviews led to the strict limitations on treatment duration and its designation as a second-line treatment.

Q: Why do some people say Нимика is a controversial drug?

A: Public discussions concerning controversy are generally linked to the medicine's documented association with an increased risk of severe liver toxicity, which includes rare cases of liver failure. This risk prompted official safety reviews by regulatory bodies and led to the current strict limitations on its use.

Q: How quickly does Нимика start working after you take it?

A: Studies and official information indicate that Nimesulide has a rapid onset of action. Clinical studies have shown that the concentration required for pain reduction can be achieved within approximately 15 minutes of the oral dose.

Q: How long do the effects of Нимика usually last?

A: Pharmacokinetic data indicates that the active substance has a relatively short elimination half-life, typically ranging from 1.8 to 4.7 hours. The medication is commonly prescribed to be administered twice daily, which is consistent with providing therapeutic coverage for a 12-hour dosing cycle.

Q: Do many people experience dizziness or drowsiness with Нимика?

A: Dizziness and drowsiness (or sleepiness) are reported as possible side effects in the official adverse reaction documentation. Official documentation notes that these effects may be experienced during treatment.

Q: Is it safe to drive or operate machinery while taking Нимика?

A: Official warnings advise that individuals who experience certain side effects should avoid driving or operating complex machinery. This guidance is given because Nimesulide may cause central nervous system effects such as dizziness or drowsiness.

Q: Does Нимика interact with common cold medicines?

A: Official information indicates that Nimesulide is generally not to be used simultaneously with other analgesics or NSAIDs. This includes those pain relievers that may be contained in over-the-counter cold and flu remedies, as combining them may increase the risk of side effects.

Q: What should I do if I think I've taken too much Нимика?

A: Symptoms of an overdose described in official literature can include fatigue, drowsiness, nausea, vomiting, and stomach pain. Regulatory documents state that immediate emergency medical attention must be sought if an overdose is suspected.

Q: Can I take Нимика if I am also taking prescription blood thinners?

A: Use requires caution. Official warnings indicate that Nimesulide may interfere with platelet function and can increase the risk of bleeding and hemorrhage when combined with anticoagulants (blood thinners) such as warfarin. Regulatory information indicates that close monitoring of the patient's condition is required.

Q: Does taking Нимика affect the effectiveness of birth control pills?

A: There is no direct official regulatory warning that Nimesulide reduces the effectiveness of hormonal birth control. However, there is documentation suggesting a potential increased risk of liver damage when Nimesulide is combined with certain oral contraceptives.

Q: Do I need a prescription to get Нимика?

A: Yes. According to regulatory status information, systemic formulations of Nimesulide (such as tablets, granules, and suppositories) are available only with a prescription in the countries where they are authorized for marketing.

Q: Is it common for people to get headaches after starting Нимика?

A: Headache is listed as a possible side effect in drug information, though it is not always classified among the most common adverse reactions. The appearance of persistent or severe headaches is a situation that should be discussed with a healthcare provider.

Q: Is it safe for a person with asthma to take Нимика?

A: No. Official documents state that Nimesulide is contraindicated if a patient has a history of allergic reactions to aspirin or other NSAIDs, particularly if those reactions involved bronchospasm (severe tightening of the airways) or wheezing.

Q: What happens if Нимика is taken while drinking alcohol?

A: Official warnings state that patients must avoid excess alcohol during treatment. Alcoholism and alcohol abuse are listed as contraindications because alcohol can significantly increase the risk of serious hepatic reactions (liver damage) associated with Nimesulide.

How should Нимика be stored and disposed of?

How to Store and Dispose of Nimesulide

Official regulatory guidelines define specific conditions for the storage and disposal of Nimesulide (Нимика) to maintain its chemical stability and ensure environmental safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 30^circC (86°F).
Container	Keep the medicine in its original package (blister and carton).
Safety	The product must be kept out of the sight and reach of children.
Stability	The medicine must not be used after the expiry date printed on the packaging.

Disposal Instructions

Used or expired Nimesulide must not be disposed of via wastewater or household waste. Disposal of any unused product must be completed according to local regulations established for pharmaceutical waste.

Нимика